PriceTargets.com logo

NASDAQ:CMPI - Checkmate Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $24.75
  • Forecasted Upside: 362.62 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$5.35 As of 07/23/2021 01:00 AM ET
▼ -0.11 (-2.01%)

This chart shows the closing price for CMPI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Checkmate Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CMPI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CMPI

Analyst Price Target is $24.75
▲ +362.62% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Checkmate Pharmaceuticals in the last 3 months. The average price target is $24.75, with a high forecast of $32.00 and a low forecast of $19.00. The average price target represents a 362.62% upside from the last price of $5.35.

This chart shows the closing price for CMPI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Checkmate Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/28/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/19/2021Jefferies Financial GroupLower Price TargetBuy$23.00 ➝ $19.00High
9/1/2020Jefferies Financial GroupInitiated CoverageBuy$22.00High
9/1/2020Bank of AmericaInitiated CoverageNeutral$19.00High
9/1/2020BMO Capital MarketsInitiated CoverageOutperform$32.00N/A
9/1/2020BTIG ResearchInitiated CoverageBuy$29.00N/A
(Data available from 7/23/2016 forward)
Checkmate Pharmaceuticals logo
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $5.35
Low: $5.16
High: $5.49

50 Day Range

MA: $6.16
Low: $5.14
High: $6.91

52 Week Range

Now: $5.35
Low: $5.00
High: $23.10

Volume

17,151 shs

Average Volume

55,178 shs

Market Capitalization

$115.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Checkmate Pharmaceuticals?

The following Wall Street sell-side analysts have issued research reports on Checkmate Pharmaceuticals in the last twelve months: Bank of America Co., BMO Capital Markets, BTIG Research, Jefferies Financial Group Inc., and Zacks Investment Research.
View the latest analyst ratings for CMPI.

What is the current price target for Checkmate Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for Checkmate Pharmaceuticals in the last year. Their average twelve-month price target is $24.75, suggesting a possible upside of 362.6%. BMO Capital Markets has the highest price target set, predicting CMPI will reach $32.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $19.00 for Checkmate Pharmaceuticals in the next year.
View the latest price targets for CMPI.

What is the current consensus analyst rating for Checkmate Pharmaceuticals?

Checkmate Pharmaceuticals currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CMPI will outperform the market and that investors should add to their positions of Checkmate Pharmaceuticals.
View the latest ratings for CMPI.

What other companies compete with Checkmate Pharmaceuticals?

Other companies that are similar to Checkmate Pharmaceuticals include Compugen, Lineage Cell Therapeutics, Oyster Point Pharma, Outlook Therapeutics, Ikena Oncology, Autolus Therapeutics, SQZ Biotechnologies, Athira Pharma, Orchard Therapeutics, Harpoon Therapeutics, Gritstone bio, Codiak BioSciences, Opthea, Black Diamond Therapeutics and Fusion Pharmaceuticals.

How do I contact Checkmate Pharmaceuticals' investor relations team?

Checkmate Pharmaceuticals' physical mailing address is 245 MAIN STREET 2ND FLOOR, CAMBRIDGE MA, 02142. The company's listed phone number is 617-682-3625. The official website for Checkmate Pharmaceuticals is www.checkmatepharma.com.